Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Delforge

Showing results (111-120 of 188) with videos related to

Pageof 19
Sort By:
Haematologica|May 25, 2010
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup TrialTheo de Witte, Anne Hagemeijer, Stefan Suciu, et al.
Annals of Hematology|August 7, 2014
Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studiesMargriet Oosterveld, Stefan Suciu, Petra Muus, et al.
Health Science Reports|January 31, 2019
Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practiceCyrille Hulin, Javier de la Rubia, Meletios A Dimopoulos, et al.
Blood|April 9, 2004
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patientsGert J Ossenkoppele, Wilfried J Graveland, Pieter Sonneveld, et al.
Haematologica|February 10, 2015
Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology OncologyBouke P C Hazenberg, Alexandra Croockewit, Bronno van der Holt, et al.
Annals of Medicine|June 18, 2013
Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physiciansJo Caers, Marie-Christiane Vekemans, Greet Bries, et al.
European Journal of Haematology|July 21, 2018
Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practiceEvangelos Terpos, Eirini Katodritou, Javier de la Rubia, et al.
Drugs|April 27, 2016
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in MyelomaPhilippe Moreau, Niels W C J van de Donk, Jesus San Miguel, et al.
Haematologica|January 22, 2026
Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/refractory multiple myeloma treated in EuropeMichele Cavo, Fredrik Schjesvold, Meletios Dimopoulos, et al.
Drugs|May 22, 2016
Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in MyelomaPhilippe Moreau, Niels W C J van de Donk, Jesus San Miguel, et al.
Pageof 19

Showing results (111-120 of 188) with videos related to

Sort By:
Pageof 19
Haematologica|May 25, 2010
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup TrialTheo de Witte, Anne Hagemeijer, Stefan Suciu, et al.
Annals of Hematology|August 7, 2014
Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studiesMargriet Oosterveld, Stefan Suciu, Petra Muus, et al.
Health Science Reports|January 31, 2019
Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practiceCyrille Hulin, Javier de la Rubia, Meletios A Dimopoulos, et al.
Blood|April 9, 2004
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patientsGert J Ossenkoppele, Wilfried J Graveland, Pieter Sonneveld, et al.
Haematologica|February 10, 2015
Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology OncologyBouke P C Hazenberg, Alexandra Croockewit, Bronno van der Holt, et al.
Annals of Medicine|June 18, 2013
Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physiciansJo Caers, Marie-Christiane Vekemans, Greet Bries, et al.
European Journal of Haematology|July 21, 2018
Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practiceEvangelos Terpos, Eirini Katodritou, Javier de la Rubia, et al.
Drugs|April 27, 2016
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in MyelomaPhilippe Moreau, Niels W C J van de Donk, Jesus San Miguel, et al.
Haematologica|January 22, 2026
Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/refractory multiple myeloma treated in EuropeMichele Cavo, Fredrik Schjesvold, Meletios Dimopoulos, et al.
Drugs|May 22, 2016
Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in MyelomaPhilippe Moreau, Niels W C J van de Donk, Jesus San Miguel, et al.
Pageof 19